Welcome to LookChem.com Sign In|Join Free
  • or
4-[5-(hydroxymethyl)thiophen-2-yl]benzaldehyde is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1220972-77-9

Post Buying Request

1220972-77-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1220972-77-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1220972-77-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,0,9,7 and 2 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1220972-77:
(9*1)+(8*2)+(7*2)+(6*0)+(5*9)+(4*7)+(3*2)+(2*7)+(1*7)=139
139 % 10 = 9
So 1220972-77-9 is a valid CAS Registry Number.

1220972-77-9Downstream Products

1220972-77-9Relevant academic research and scientific papers

Palladium-catalysed direct arylation of heteroaromatics bearing unprotected hydroxyalkyl functions using aryl bromides

Roger, Julien,Pozgan, Franc,Doucet, Henri

experimental part, p. 696 - 710 (2010/06/19)

Heteroaromatics bearing unprotected hydroxyalkyl functions can be arylated using aryl or heteroaryl bromides, via palladium-catalysed carbonhydrogen bond activation/arylation. Good yields were generally obtained using 0.01-0.5 mol% of the air-stable palladium acetate complex as the catalyst. The nature of the base was found to be crucial for the selectivity of this reaction. Potassium acetate led to the direct arylation products whereas caesium car-bonate led to the formation of the ether. This procedure is certainly more atom-economic than other methods for the preparation of such compounds, as no protection/ deprotection sequence of the hydroxyalkyl function and no preparation of an organometallic derivative is required.

S1P RECEPTORS MODULATORS AND THEIR USE THEREOF

-

Page/Page column 69, (2010/04/30)

The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1220972-77-9